Lung cancer is the commonest cancer killer. Small cell lung cancer (SCLC) is initially
chemosensitive, but rapidly relapses in a chemoresistant form with an overall survival of< …

Background We previously identified amplification of the fibroblast growth factor receptor 1
gene (FGFR1) as a potential therapeutic target for small-molecule inhibitor therapy in …

The FGFR signaling pathway has a crucial role in proliferation, survival, and migration of
cancer cells, tumor angiogenesis, and drug resistance. FGFR genetic abnormalities, such as …

Small cell lung cancer (SCLC) remains a recalcitrant disease where limited therapeutic
options have not improved overall survival, and approved targeted therapies are lacking …

The fibroblast growth factor (FGF) signaling axis is increasingly implicated in tumorigenesis
and chemoresistance. Several small-molecule FGF receptor (FGFR) kinase inhibitors are …

Aberrant fibroblast growth factor receptor (FGFR) activation/expression is a common feature
in lung cancer (LC). In this study, we evaluated the antitumor activity of and the mechanisms …

Small-cell lung cancer (SCLC) comprises about 13–15% of all lung cancers, and more than
29 400 new cases have been diagnosed in the United States in the year 2012. SCLC is a …

The involvement of fibroblast growth factor-2 (FGF-2) in the biology of small cell lung cancer
(SCLC) has not previously been investigated. Here we report that FGF-2 prevented …

Fibroblast growth factors (FGFs) signal through FGF receptors (FGFRs), which are a sub-
family of the superfamily of receptor tyrosine kinases, to regulate human development and …

Abstract Purpose: The 8p12-p11 locus is frequently amplified in squamous cell lung cancer
(SQLC); the receptor tyrosine kinase fibroblast growth factor receptor 1 (FGFR1) being one …